{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:33:00Z","timestamp":1781620380598,"version":"3.54.5"},"reference-count":81,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Following the Ebola outbreak in Western Africa in 2013\u201316, a global effort has taken place for preparedness for future outbreaks. As part of this response, the development of vaccines, treatments and diagnostic tools has been accelerated, especially towards pathogens listed as likely to cause an epidemic and for which there are no current treatments. Several of the priority pathogens identified by the World Health Organisation are haemorrhagic fever viruses. This review provides information on the role of reference materials as an enabling tool for the development and evaluation of assays, and ultimately vaccines and treatments. The types of standards available are described, along with how they can be applied for assay harmonisation through calibration as a relative potency to a common arbitrary unitage system (WHO International Unit). This assures that assay metrology is accurate and robust. We describe reference materials that have been or are being developed for haemorrhagic fever viruses and consider the issues surrounding their production, particularly that of biosafety where the viruses require specialised containment facilities. Finally, we advocate the use of reference materials at early stages, including research and development, as this helps produce reliable assays and can smooth the path to regulatory approval.<\/jats:p>","DOI":"10.3390\/v11090781","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T04:38:23Z","timestamp":1566794303000},"page":"781","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Role of Reference Materials in the Research and Development of Diagnostic Tools and Treatments for Haemorrhagic Fever Viruses"],"prefix":"10.3390","volume":"11","author":[{"given":"Giada","family":"Mattiuzzo","sequence":"first","affiliation":[{"name":"Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-2840","authenticated-orcid":false,"given":"Emma M.","family":"Bentley","sequence":"additional","affiliation":[{"name":"Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Page","sequence":"additional","affiliation":[{"name":"Division of Virology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"key":"ref_1","first-page":"473","article-title":"Diphtheria Antigens-Their Preparation, Properties, Laboratory Testing and Statutory Control","volume":"38","author":"Hartley","year":"1945","journal-title":"Proc. R. Soc. Med."},{"key":"ref_2","first-page":"45","article-title":"International Biological Standards: Prospect and Retrospect","volume":"39","author":"Hartley","year":"1945","journal-title":"Proc. R. Soc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1098\/rsnr.2006.0153","article-title":"Standardization of biological medicines: The first hundred years, 1900\u20132000","volume":"60","author":"Bristow","year":"2006","journal-title":"Notes Rec. R. Soc. Lond."},{"key":"ref_4","unstructured":"WHO (2006). Recommendations for the Preparation, Characterization and Establishment of International and Other Biological Reference Standards (WHO Technical Report Series No. 932), World Health Organization."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jcp.2003.015545","article-title":"The management of external quality assurance","volume":"58","author":"Sandle","year":"2005","journal-title":"J. Clin. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jcrc.2017.11.006","article-title":"Viral hemorrhagic fever in the tropics: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine","volume":"42","author":"Hidalgo","year":"2017","journal-title":"J. Crit. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/civ792","article-title":"Viral Hemorrhagic Fever Diagnostics","volume":"62","author":"Racsa","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.idc.2012.02.003","article-title":"Arboviruses and viral hemorrhagic fevers (VHF)","volume":"26","author":"Meltzer","year":"2012","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/CMR.00003-16","article-title":"Diagnosis of Ebola Virus Disease: Past, Present, and Future","volume":"29","author":"Broadhurst","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1863-2378.2012.01477.x","article-title":"Flexibility of mobile laboratory unit in support of patient management during the 2007 Ebola-Zaire outbreak in the Democratic Republic of Congo","volume":"59","author":"Grolla","year":"2012","journal-title":"Zoonoses Public Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1086\/520601","article-title":"High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings","volume":"196","author":"Towner","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/infdis\/jiy362","article-title":"Development of Mobile Laboratory for Viral Hemorrhagic Fever Detection in Africa","volume":"218","author":"Weidmann","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30055","DOI":"10.2807\/1560-7917.ES.2015.20.44.30055","article-title":"Mobile diagnostics in outbreak response, not only for Ebola: A blueprint for a modular and robust field laboratory","volume":"20","author":"Wolfel","year":"2015","journal-title":"Eur. Surveill."},{"key":"ref_14","unstructured":"FDA (2019, July 11). Emergency Use Authorizations. United States Food and Drug Administration, Available online: https:\/\/www.fda.gov\/medical-devices\/emergency-situations-medical-devices\/emergency-use-authorizations#ebola."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7861\/clinmedicine.15-1-61","article-title":"Viral haemorrhagic fever","volume":"15","author":"Fhogartaigh","year":"2015","journal-title":"Clin. Med. (Lond.)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"Warner","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijid.2017.11.007","article-title":"The challenges of detecting and responding to a Lassa fever outbreak in an Ebola-affected setting","volume":"66","author":"Hamblion","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e001112","DOI":"10.1136\/bmjgh-2018-001112","article-title":"Diagnostics for filovirus detection: Impact of recent outbreaks on the diagnostic landscape","volume":"4","author":"Emperador","year":"2019","journal-title":"BMJ Glob. Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e001116","DOI":"10.1136\/bmjgh-2018-001116","article-title":"Diagnostics for Lassa fever virus: A genetically diverse pathogen found in low-resource settings","volume":"4","author":"Mazzola","year":"2019","journal-title":"BMJ Glob. Health"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nikisins, S., Rieger, T., Patel, P., Muller, R., Gunther, S., and Niedrig, M. (2015). International external quality assessment study for molecular detection of Lassa virus. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003793"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bartolini, B., Gruber, C.E., Koopmans, M., Avsic, T., Bino, S., Christova, I., Grunow, R., Hewson, R., Korukluoglu, G., and Lemos, C.M. (2019). Laboratory management of Crimean-Congo haemorrhagic fever virus infections: Perspectives from two European networks. Eur. Surveill., 24.","DOI":"10.2807\/1560-7917.ES.2019.24.5.1800093"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-3542(02)00201-2","article-title":"Molecular diagnostics of viral hemorrhagic fevers","volume":"57","author":"Drosten","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e001114","DOI":"10.1136\/bmjgh-2018-001114","article-title":"Diagnostic tests for Crimean-Congo haemorrhagic fever: A widespread tickborne disease","volume":"4","author":"Mazzola","year":"2019","journal-title":"BMJ Glob. Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4269\/ajtmh.2010.09-0636","article-title":"Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses","volume":"82","author":"Trombley","year":"2010","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_25","unstructured":"(2019, July 11). UK Vaccine Network, Available online: https:\/\/www.gov.uk\/government\/groups\/uk-vaccines-network."},{"key":"ref_26","unstructured":"WHO (2018, January 6\u20137). 2018 Annual review of diseases prioritized under the Research and Development Blueprint Informal consultation. Proceedings of the Workshop on Prioritization of Pathogens, Geneva, Switzerland."},{"key":"ref_27","unstructured":"SAGE Working Group on Dengue Vaccine and WHO Secretariat (2019, July 11). Background Paper on Dengue Vaccines. Available online: https:\/\/www.who.int\/immunization\/sage\/meetings\/2018\/april\/2_DengueBackgrPaper_SAGE_Apr2018.pdf?ua=1."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1016\/j.vaccine.2017.03.032","article-title":"Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease","volume":"35","author":"Barrett","year":"2017","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40259-018-0329-7","article-title":"Current Ebola Virus Vaccine Progress","volume":"33","author":"Marzi","year":"2019","journal-title":"BioDrugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1016\/j.vaccine.2017.07.054","article-title":"Vaccines against Ebola virus","volume":"36","author":"Venkatraman","year":"2018","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/21645515.2016.1225637","article-title":"Ebola vaccines in clinical trial: The promising candidates","volume":"13","author":"Wang","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.29245\/2578-3009\/2018\/si.1111","article-title":"The Role of the African Vaccine Regulatory Forum (AVAREF) in the Accelerated Clinical Evaluation of Ebola Vaccine Candidates During the Large West Africa Epidemic","volume":"S (011)","author":"Akanmori","year":"2018","journal-title":"J. Immunol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.coviro.2016.03.008","article-title":"On a path to accelerate access to Ebola vaccines: The WHO\u2019s research and development efforts during the 2014\u20132016 Ebola epidemic in West Africa","volume":"17","author":"Preziosi","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1016\/j.vaccine.2017.05.031","article-title":"Development of vaccines against Crimean-Congo haemorrhagic fever virus","volume":"35","author":"Dowall","year":"2017","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C., and Richt, J.A. (2017). Current Status of Rift Valley Fever Vaccine Development. Vaccines (Basel.), 5.","DOI":"10.3390\/vaccines5030029"},{"key":"ref_37","unstructured":"CEPI (2019, July 11). Coalition for Epidemic Preparendess Innovations. Available online: https:\/\/cepi.net\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1080\/21645515.2017.1306615","article-title":"Vaccines for epidemic infections and the role of CEPI","volume":"13","author":"Plotkin","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/infdis\/155.3.437","article-title":"A prospective study of the epidemiology and ecology of Lassa fever","volume":"155","author":"McCormick","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_40","unstructured":"NCDC (2019, July 11). 2019 Lassa Fever Outbreak Situation Report, Available online: https:\/\/ncdc.gov.ng\/themes\/common\/files\/sitreps\/28e15c98c6b1da4232f2d3a4b2db40b5.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","article-title":"Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018","volume":"379","author":"Siddle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_42","unstructured":"WHO (2019, July 11). Technical Guidance on Lassa Fever. Available online: https:\/\/www.who.int\/emergencies\/diseases\/lassa-fever\/technical-guidance\/en\/."},{"key":"ref_43","unstructured":"WHO (2019, July 11). WHO Target Product Profile for Lassa Virus Vaccine. Available online: https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/LassaVirusVaccineTPP.PDF?ua=1."},{"key":"ref_44","unstructured":"WHO (2019, July 11). Disease Outbreaks. Crimean-Congo Haemorrhagic Fever (CCHF). Available online: https:\/\/www.who.int\/emergencies\/diseases\/crimean-congo-haemorrhagic-fever\/en\/."},{"key":"ref_45","unstructured":"WHO (2019, July 11). R&D Blueprint Crimean-Congo Haemorrhagic Fever (CCHF). Available online: https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/crimean-congo-haemorrhagic-fever\/en\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2460\/javma.234.7.883","article-title":"Rift Valley fever virus","volume":"234","author":"Bird","year":"2009","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fawzy, M., and Helmy, Y.A. (2019). The One Health Approach is Necessary for the Control of Rift Valley Fever Infections in Egypt: A Comprehensive Review. Viruses, 11.","DOI":"10.3390\/v11020139"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/trf.14130","article-title":"Collaborative study to establish World Health Organization international reference reagents for dengue virus Types 1 to 4 RNA for use in nucleic acid testing","volume":"57","author":"Anez","year":"2017","journal-title":"Transfusion"},{"key":"ref_49","unstructured":"Public Health Agency of Canada (2019, July 11). Human Pathogens and Toxins Act (HPTA). Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/laboratory-biosafety-biosecurity\/human-pathogens-toxins-act\/security-sensitive-biological-agents.html."},{"key":"ref_50","unstructured":"(2000). Directive 2000\/54\/EC of the European Parliament and the Council of 18 September 2000 on the Protection of Workers from Risks Related to Exposure to Biological Agents at Work (Seventh Individual Directive within the Meaning of Article 16(1) of Directive 89\/391\/EEC). Off. J. L, 262, 21\u201345. Available online: http:\/\/data.europa.eu\/eli\/dir\/2000\/54\/oj."},{"key":"ref_51","unstructured":"Advisory Committee on Dangerous Pathogens, Health and Safety Executive (2019, July 11). The Approved List of Biological Agents, Available online: http:\/\/www.hse.gov.uk\/pubns\/misc208.pdf."},{"key":"ref_52","unstructured":"U.S. Department of Health and Human Services, Public Health Service, Centre for Disease Control and Prevention, National Institute of Health (2009). Biosafety in Microbiological and Biomedical Laboratories, no. (CDC) 21-1112."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/jcm.20.3.486-489.1984","article-title":"Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses","volume":"20","author":"Mitchell","year":"1984","journal-title":"J. Clin. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/JCM.01449-15","article-title":"Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample Type","volume":"53","author":"Smither","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_55","unstructured":"WHO (2016). Expert Committee on Biological Standardization, Sixty-Sixth Report (WHO Technical Report Series No. 999), World Health Organization."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mattiuzzo, G., Ashall, J., Doris, K.S., MacLellan-Gibson, K., Nicolson, C., Wilkinson, D.E., Harvey, R., Almond, N., Anderson, R., and Efstathiou, S. (2015). Development of Lentivirus-Based Reference Materials for Ebola Virus Nucleic Acid Amplification Technology-Based Assays. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142751"},{"key":"ref_57","unstructured":"Wilkinson, D.E., Page, M., Almond, N., Anderson, R., Ashall, J., Berry, N., Doris, K.S., Efsthatiou, S., Harvey, R., and Hassall, M. (2019, August 23). WHO Collaborative Study to Assess the Suitability of Interim Standards for Ebola Virus NAT Assays 2015. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/197763\/WHO_BS_2015.2279_eng.pdf?sequence=1&isAllowed=y."},{"key":"ref_58","unstructured":"WHO (2018). Expert Committee on Biological Standardization, Sixty-Eighth Report (WHO Technical Report Series No. 1011), World Health Organization."},{"key":"ref_59","unstructured":"WHO (2019). Expert Committee on Biological Standardization, Sixty-Ninth Report (WHO Technical Report Series No. 1016), World Health Organization."},{"key":"ref_60","unstructured":"WHO (1963). Expert Committee on Biological Standardization, Fifteenth Report (WHO Technical Report Series No. 259), World Health Organization."},{"key":"ref_61","unstructured":"WHO (2004). Expert Committee on Biological Standardization, Fifty-Sixth Report (WHO Technical Series No. 941), World Health Organization."},{"key":"ref_62","unstructured":"WHO (2017). Expert Committee on Biological Standardization, Sixty-Seventh Report (WHO Technical Report Series No.1004), World Health Organization."},{"key":"ref_63","first-page":"243","article-title":"International collaborative assay of the international reference preparation of anti-yellow-fever serum","volume":"33","author":"Krag","year":"1965","journal-title":"Bull. World Health Organ."},{"key":"ref_64","first-page":"139","article-title":"Reference materials and commutability","volume":"28","author":"Vesper","year":"2007","journal-title":"Clin. Biochem. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1128\/JCM.01706-16","article-title":"Commutability of the World Health Organization International Standard for Human Cytomegalovirus: Standard or Assay","volume":"54","author":"Fryer","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3201\/eid2502.180798","article-title":"International Biological Reference Preparations for Epidemic Infectious Diseases","volume":"25","author":"Rampling","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.vaccine.2016.11.083","article-title":"Comparison of platform technologies for assaying antibody to Ebola virus","volume":"35","author":"Wilkinson","year":"2017","journal-title":"Vaccine"},{"key":"ref_68","unstructured":"Wilkinson, D.H.M., Mattiuzzo, G., Stone, L., Atkinson, E., Hockley, J., Rigsby, P., Di Caro, A., McLennan, S., Olaussen, R.W., and Rijal, P. (2019, August 23). WHO Collaborative Study to Assess the Suitability of the 1st International Standard and the 1st International Reference Panel for Antibodies to Ebola Virus 2017. Available online: https:\/\/www.who.int\/biologicals\/expert_committee\/BS2316_Anti-EBOV_Antibodies_WHO_1st_IS_and_WHO_1st_International_Ref_Panel.pdf."},{"key":"ref_69","unstructured":"WHO (2014). Target Product Profile for Za\u00efre Ebolavirus Rapid, Simple Test to be Used in the Control of the Ebola Outbreak in West Africa, World Health Organization."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(18)30277-9","article-title":"Early detection of Lassa fever: The need for point-of-care diagnostics","volume":"18","author":"Dhillon","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/JCM.00707-17","article-title":"Progress and Challenges towards Point-of-Care Diagnostic Development for Dengue","volume":"55","author":"Pang","year":"2017","journal-title":"J. Clin. Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2004.09.003","article-title":"Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine","volume":"32","author":"Ferguson","year":"2004","journal-title":"Biologicals"},{"key":"ref_73","unstructured":"WHO (1998). Requirements for Yellow Fever Vaccine (Requirements for Biological Substances No.3), World Health Organization. WHO Expert Committee on Biological Standardization, Forty-Sixth Report (WHO Technical Report Series No. 872)."},{"key":"ref_74","unstructured":"WHO (2019, July 11). Immunization, Vaccines and Biologicals\u2014Questions and Answers on Dengue Vaccines. Available online: https:\/\/www.who.int\/immunization\/research\/development\/dengue_q_and_a\/en\/."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: A single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Coxon, C.H., Longstaff, C., and Burns, C. (2019). Applying the science of measurement to biology: Why bother?. PLoS Biol., 17.","DOI":"10.1371\/journal.pbio.3000338"},{"key":"ref_78","unstructured":"Innovative UK (2019, July 11). Available online: www.gov.uk\/government\/organisations\/innovate-uk."},{"key":"ref_79","unstructured":"(2019, July 11). Foundation for Innovative New Diagnostics (FIND). Available online: https:\/\/www.finddx.org\/at-a-glance\/."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/fvl-2017-0003","article-title":"Developing biological standards for vaccine evaluation","volume":"12","author":"Page","year":"2017","journal-title":"Future Virol."},{"key":"ref_81","unstructured":"WHO (1992). Guidelines for National Authorities on Quality Assurance for Biological Products (WHO Technical Report SERIES No. 822), World Health Organization."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/9\/781\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:13:43Z","timestamp":1760188423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/9\/781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":81,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["v11090781"],"URL":"https:\/\/doi.org\/10.3390\/v11090781","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]}}}